Adenoviral transfer of vasoactive intestinal peptide (VIP) gene inhibits rat aortic and pulmonary artery smooth muscle cell proliferation

Peptides

Volumn 30, Issue 12, 2009, Pages 2323-2329

  St Hilaire, Rose Claire ^a   Kadowitz, Philip J ^a   Jeter Jr , James R ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cAMP; Pulmonary hypertension; Vascular smooth muscle cells; Vasodilators

Indexed keywords

ADENOVIRUS VECTOR; CYCLIC AMP; VASOACTIVE INTESTINAL POLYPEPTIDE;

ADENOVIRUS 5; ANIMAL CELL; ANIMAL EXPERIMENT; AORTA; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENETIC TRANSFECTION; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; PULMONARY ARTERY; RAT; SEROTYPE; SMOOTH MUSCLE FIBER; VASODILATATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; WESTERN BLOTTING;

8-BROMO CYCLIC ADENOSINE MONOPHOSPHATE; ADENOVIRIDAE; ANIMALS; BLOTTING, WESTERN; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CYCLIC AMP-DEPENDENT PROTEIN KINASES; GENETIC VECTORS; HYPERTENSION, PULMONARY; IMMUNOHISTOCHEMISTRY; MALE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; RATS; RATS, SPRAGUE-DAWLEY; THIONUCLEOTIDES; VASOACTIVE INTESTINAL PEPTIDE;

ADENOVIRIDAE; RATTUS;

EID: 70449685795     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2009.08.010     Document Type: Article

References (32)

1. Agata J., Zhang J.J., Chao J., and Chao L. Adrenomedullin gene delivery inhibits neointima formation in rat artery after balloon angioplasty. Regul Pept 112 1-3 (2003) 115-120
2. Annaid S., Petkov V., Baykuscheva-Gentscheva T., Hoeger H., Painsipp E., and Mosgoeller W. Involvement of endothelial NO in the dilator effect of VIP on isolated pulmonary artery. Regul Pept 139 1-3 (2007) 102-108
3. Champion H.C., Bivalacqua T.J., Toyoda K., Heistad D.D., Hyman A.L., and Kadowitz P.J. In vivo gene transfer of prepro-calcitonin gene related peptide to the lung attenuates chronic hypoxia-induced pulmonary hypertension in the mouse. Circulation 101 (2000) 923-930
4. Channon K.M., Qian H., and George S.E. Nitric oxide synthase in atherosclerosis and vascular injury: insights from experimental gene therapy. Arterioscler Thromb Vasc Biol 20 8 (2000) 1873-1881
5. Chattergoon N.N., D'Souza F.M., Deng W., Chen H., Hyman A.L., Kadowitz P.J., et al. Antiproliferative effects of calcitonin gene-related peptide in aortic and pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 288 1 (2005) L202-L211
6. D'Souza F.M., Sparks R.L., Chen H., Kadowitz P.J., and Jeter Jr. J.R. Mechanism of eNOS gene transfer inhibition of vascular smooth muscle cell proliferation. Am J Physiol Lung Cell Mol Physiol 284 (2003) C191-C199
7. Fager G., Hansson G.K., Gown A.M., Larson D.M., Skalli O., and Bondjers G. Human arterial smooth muscle cells in culture: inverse relationship between proliferation and expression of contractile proteins. In Vitro Cell Dev Biol 25 6 (1989) 511-520
8. Ganz P., Sandrock A.W., Landis S.C., Leopold J., Gimbrone Jr. M.A., and Alexander R.W. Vasoactive intestinal peptide: vasodilation and cyclic AMP generation. Am J Physiol 250 5 (1986) 755-760
9. Greenberg B., Rhoden K., and Barnes P.J. Relaxant effects of vasoactive intestinal peptide and peptide histidine isoleucine in human and bovine pulmonary arteries. Blood Vessels 24 (1987) 45-50
10. Gunaydin S., Imai Y., Takanashi Y., Seo K., Hagino I., Chang D., et al. The effects of vasoactive intestinal peptide on monocrataline induced pulmonary hypertensive rabbits following cardiopulmonary bypass: a comparative study with isoproteronol and nitroglycerine. Cardiovasc Surg 10 (2002) 138-145
11. Haberl I., Frei K., Ramsebner R., Doberer D., Petkov V., Albinni S., et al. Vasoactive intestinal peptide gene alterations in patients with idiopathic pulmonary arterial hypertension. Eur J Hum Genet 15 1 (2007) 18-22
12. Hamidi S.A., Prabhakar S., and Said S.I. Enhancement of pulmonary vascular remodeling and inflammatory genes with VIP gene deletion. Eur Respir J 31 (2008) 135-139
13. Hultgardh-Nilsson A., Nilsson J., Jonzon B., and Dalsgaard C.J. Growth-inhibitory properties of vasoactive intestinal polypeptide. Regul Pept 22 (1988) 267-274
14. Igarashi H., Ito T., Mantey S.A., Pradhan T.K., Hou W., Coy D.H., et al. Development of simplified vasoactive intestinal peptide analogs with receptor selectivity and stability for human vasoactive intestinal peptide/pituitary adenylate cyclase-activating polypeptide receptors. J Pharmacol Exp Ther 315 1 (2005) 370-381
15. Kano H., Kohno M., Yasunari K., Yokokawa K., Horio T., Ikeda M., et al. Adrenomedullin as a novel antiproliferative factor of vascular smooth muscle cells. J Hypertens 14 2 (1996) 209-213
16. Kim B.J., Lee J.H., Jun J.Y., Chang I.Y., So I., and Kim K.W. Vasoactive intestinal polypeptide inhibits pacemaker activity via the nitric oxide-protein kinase G pathway in the interstitial cells of Cajal of the murine small intestine. Mol Cells 21 3 (2006) 337-342
17. Laburthe M., and Couvineau A. Molecular pharmacology and structure of VPAC receptors for VIP and PACAP. Regul Pept 108 (2002) 165-173
18. Laburthe M., Couvineau A., and Voisin T. Receptors for peptides of the VIP/PACAP and PYY/NPY/PP. Gastrointest Endocrinol 9 (1999) 125-157
19. Larsson L.I., Fahrenkrug J., Schaffalitzky De Muckadell O., Sundler F., Hakason R., and Rehfeld J.R. Localization of vasoactive intestinal peptide (VIP) to central and peripheral neurons. Proc Natl Acad Sci 73 (1976) 3197-3300
20. Lodde B.M., Delporte C., Goldsmith C.M., Tak P.P., and Baum B.J. A recombinant adenoviral vector encoding functional vasoactive intestinal peptide. Biochem Biophys Res Comm 319 (2004) 189-192
21. Maruno K., Absood A., and Said S.I. VIP inhibits basal and histamine-stimulated proliferation of airway smooth muscle cells. Am J Physiol 268 (1995) L1047-L1051
22. McKay M.J., and Gaballa M.A. Gene transfer therapy in vascular diseases. Cardiovasc Drug Rev 19 3 (2001) 245-262
23. Murray K.J. Cyclic AMP and mechanisms of vasodilation. Pharmac Ther 47 3 (1990) 329-345
24. Nabel E.G. Gene therapy for vascular disease. Atherosclerosis 118 Suppl. (1995) S51-S56
25. Nandiwada P.A., Kadowitz P.J., Said S.I., Mojarad M., and Hyman A.L. Pulmonary vasodilator responses to vasoactive intestinal peptide in the cat. J Appl Physiol 58 (1985) 1723-1728
26. Ohno T., Gordon D., San H., Pompili V.J., Imperiale M.J., and Nabel G.J. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science 265 (1994) 781-784
27. Petkov V., Mosgoeller W., Ziesche R., Raderer M., Stiebellehner L., Vonbank K., et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 111 9 (2003) 1339-1346
28. Said S.I., Hamidi S.A., Dickman K.G., Szema A.M., Lyubsky S., Lin R.Z., et al. Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene. Circulation 115 10 (2007) 1260-1268
29. Said S.I., and Mutt V. Polypeptide with broad biological activity isolation from small intestine. Science 169 (1970) 1217-1218
30. Sata T., Linden J., Liu L.W., Kubota E., and Said S.I. Vasoactive intestinal peptide evokes endothelium-dependent relaxation and cyclic AMP accumulation in rat aorta. Peptides 9 4 (1988) 853-858
31. Soderman C., Eriksson L.S., Juhlin-Dannfelt A., Lundberg J.M., Broman L., and Holmgren A. Effect of vasoactive intestinal polypeptide (VIP) on pulmonary ventilation-perfusion relationships and central haemodynamics in healthy subjects. Clin Physiol 13 6 (1993) 677-685
32. Voelkel N.F., and Tuder R.M. Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension. Eur Respir J 8 (1995) 2129-2138